Study to Show Non-inferiority of Tritanrix-HepB/Hib-MenAC (+/- Hepatitis B Vaccine at Birth) vs Tritanrix-HepB/Hiberix Without Hepatitis B Vacc. at Birth for Antibody Response to All Vaccine Antigens Given in Healthy Infants

Trial Profile

Study to Show Non-inferiority of Tritanrix-HepB/Hib-MenAC (+/- Hepatitis B Vaccine at Birth) vs Tritanrix-HepB/Hiberix Without Hepatitis B Vacc. at Birth for Antibody Response to All Vaccine Antigens Given in Healthy Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Hib-DTP-hepatitis B-meningococcal vaccine groups A and C conjugate (Primary) ; Hepatitis B vaccine; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix)
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group A infections; Meningococcal group C infections; Meningococcal infections; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top